Outcome According to Tumor Ras Mutation Status in Crystal Study Patients with Metastatic Colorectal Cancer Randomized to Folfiri with or Without Cetuximab as First-Line Treatment

Autor:	H. van Krieken, Sabine Tejpar, Klaus Duecker, J. Lenz Heinz, Frank Beier, Fortunato Ciardiello, E. Van Cutsem, I. Melezinek, C.-H. Köhne, Volker Heinemann
Rok vydání:	2014
Předmět:	Oncology medicine.medical_specialty Cetuximab business.industry Colorectal cancer Hematology medicine.disease First line treatment Internal medicine RAS Mutation Mutation (genetic algorithm) medicine FOLFIRI business medicine.drug
Zdroj:	Annals of Oncology. 25:ii113
ISSN:	0923-7534
DOI:	10.1093/annonc/mdu193.20
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a39e98e14b84169f6571be8de51741bd https://doi.org/10.1093/annonc/mdu193.20 Zobrazit plný text záznamu